Chłoniak: badanie kliniczne fazy I

Kryteria wyłączenia kto nie może wziąć udziału (17)

1. All Participants
2. Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).
3. Known or suspected central nervous system (CNS) involvement by systemic lymphoma.
4. Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
5. Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.
6. Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.
7. Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.
8. Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).
9. Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval.
10. History of autoimmune disease
11. Significant cardiovascular disease
12. Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process
13. Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF).
14. Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).
15. Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody).
16. Pregnant and/or planning to breastfeed during the trial or within 90 days of the last dose of study intervention.
17. Known hypersensitivity to any component or excipient of LY4152199.